FDA issues complete response letter for obeticholic acid for fibrosis due to NASH

The FDA issued a complete response letter for the new drug application for obeticholic acid for treatment of fibrosis due to nonalcoholic steatohepatitis, according to a press release from Intercept Pharmaceutical Inc.“Today represents a setback first and foremost for NASH patients with advanced fibrosis who have bene waiting far too long for a therapy to treat their disease,” Mark Pruzanski, MD, president and CEO of Intercept, said during a conference call. “It has been an extraordinarily challenging program to get to this point and we believe that we have convincing dataRead More

Share on facebook
Share on twitter
Share on linkedin